AstraZeneca Launches Zegfrovy Lung Cancer Drug in US
AstraZeneca announced the U.S. launch of Zegfrovy (sunvozertinib), indicated for adults with locally advanced or metastatic non-small cell lung cancer carrying EGFR exon 20 insertions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.